Filtered By:
Condition: Patent Foramen Ovale

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 1415 results found since Jan 2013.

Cryptogenic Stroke and Patent Foramen Ovale Risk Assessment
Publication date: Available online 29 June 2017 Source:Interventional Cardiology Clinics Author(s): Emiliya Melkumova, David E. ThalerTeaser Stroke is a devastating condition. It is the fifth leading cause of death in the United States, and a leading cause of serious long-term disability. Stroke occurs at any age. Younger patients tend to have strokes of undetermined cause, termed cryptogenic. Herein, the authors describe the classification of stroke cause; the risk of recurrent cryptogenic stroke with patent foramen ovale (PFO); a risk assessment model to stratify incidental versus a pathogenic PFO in patients presenting...
Source: Interventional Cardiology Clinics - June 30, 2017 Category: Cardiology Source Type: research

Clinical outcomes of secondary prevention strategies for young patients with cryptogenic stroke and patent foramen ovale.
Conclusions The diagnosis of stroke in patients with PFO could be confirmed in 50% of cases only, underlining the importance of a multidisciplinary evaluation of these patients. A very low ischaemic recurrence rate was observed in the medical therapy group, suggesting that a personalized treatment based on a prespecified diagnostic algorithm yields good clinical results irrespective of the treatment modality. Given the low number of recurrences, larger cohorts may be needed to prove significant differences. PMID: 28705105 [PubMed - as supplied by publisher]
Source: Acta Cardiologica - July 15, 2017 Category: Cardiology Tags: Acta Cardiol Source Type: research

Percutaneous closure of a  patent foramen ovale after cryptogenic stroke.
Percutaneous closure of a patent foramen ovale after cryptogenic stroke. Neth Heart J. 2017 Dec 04;: Authors: Snijder RJR, Suttorp MJ, Ten Berg JM, Post MC Abstract A patent foramen ovale is a common intracardiac finding that is located between the left and right atrium. It can cause right-to-left shunting and has a high prevalence in patients who suffer a cryptogenic stroke. Earlier trials did not show superiority of percutaneous patent foramen ovale closure with standard medical therapy over standard medical therapy alone in the treatment of cryptogenic stroke. Interestingly, several meta-analy...
Source: Netherlands Heart Journal - December 4, 2017 Category: Cardiology Authors: Snijder RJR, Suttorp MJ, Ten Berg JM, Post MC Tags: Neth Heart J Source Type: research

Microbubble signal and trial of org in acute stroke treatment (TOAST) classification in ischemic stroke
Right-to-left shunt (RLS) through a patent foramen ovale (PFO) is likely associated with ischemic stroke. Many studies have attempted to demonstrate the association between RLS and ischemic stroke. However, information on the association between the degree of RLS and the subtypes of ischemic stroke categorized by the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification is lacking.
Source: Journal of the Neurological Sciences - April 20, 2018 Category: Neurology Authors: Chan-Hyuk Lee, Hyun Goo Kang, Ji Sung Lee, Han Uk Ryu, Seul-Ki Jeong Source Type: research

Patent foramen ovale increases stroke risk in older people
Patent foramen ovale increases stroke risk in older people, Published online: 27 July 2018; doi:10.1038/s41582-018-0050-7Patent foramen ovale (PFO) is prevalent among young patients with cryptogenic stroke, and PFO closure reduces the risk of recurrent stroke in these individuals. A new study confirms that PFO is also frequent in patients with cryptogenic stroke aged >60 years, but the optimal management of such patients remains unresolved.
Source: Nature Reviews Neurology - July 27, 2018 Category: Neurology Authors: Heinrich P. Mattle Jeffrey L. Saver Source Type: research

Management of patent foramen ovale in patients with cryptogenic stroke: Is device closure superior to medical treatment? A brief review.
Conclusion: In cryptogenic stroke patients <60 years with large PFOs, PFO closure seems to be safe and more effective compared to medical treatment alone. For all other patients group, for example, patients >60 years further trials are needed to clarify the role of PFO closure. PMID: 30105130 [PubMed]
Source: Surgical Neurology International - August 16, 2018 Category: Neurosurgery Tags: Surg Neurol Int Source Type: research

Updated Meta-analysis on the Closure of Patent Foramen Ovale in Reduction of Stroke Rates: the DEFENSE-PFO Trial Does not Change the Scenario
Conclusion: This meta-analysis found that stroke rates are lower with percutaneously implanted device closure than with medical therapy alone, being these rates modulated by the rates of hypertension, atrial septal aneurysm and effective closure. The publication of a new trial did not change the scenario in the medical literature.
Source: Revista Brasileira de Cirurgia Cardiovascular - December 13, 2018 Category: Cardiovascular & Thoracic Surgery Source Type: research

Closure of the patent foramen ovale (PFO) in cryptogenic stroke.
Authors: Diener HC, Knebel F Abstract Autopsy studies and echocardiographic investigations have shown that around 20-25% of the healthy population have a patent foramen ovale (PFO). In patients younger than 55 years the risk of a cryptogenic stroke is increased in the presence of a PFO. The first three randomized studies could not demonstrate superiority of an interventional closure of a PFO compared to antithrombotic treatment in patients with cryptogenic stroke. The results of three recently published studies and the extension of an earlier study showed a superiority of an interventional closure of a PFO comp...
Source: Herz - April 5, 2019 Category: Cardiology Tags: Herz Source Type: research

Device Closure of Patent Foramen Ovale for Cryptogenic Stroke: Patient Selection and Outcomes According to New Randomized Trials
AbstractPurpose of ReviewThis review summarizes the most recent randomized clinical trials that studied the role of device-mediated patent foramen ovale (PFO) closure in patients after an ischemic stroke presumed to have been caused by a paradoxical embolism.Recent FindingsThree major randomized trials published in 2017 studied the strategy of using PFO closure for secondary prevention in patients between the ages of 18 and 60 who presented with an index stroke having characteristics of an embolic mechanism. All patients had a PFO that potentially could have enabled paradoxical embolism and other causes of stroke were excl...
Source: Current Cardiology Reports - April 21, 2019 Category: Cardiology Source Type: research

Patent Foramen Ovale Closure Versus Medical Therapy for Cryptogenic Stroke: An Updated Systematic Review and Meta-Analysis
ConclusionPFO closure is associated with a significant reduction in the risk of stroke compared to medical management. However, it causes an increased risk of atrial fibrillation.
Source: Indian Heart Journal - October 22, 2019 Category: Cardiology Source Type: research

Role of PFO Closure in Ischemic Stroke Prevention
AbstractPurpose of reviewTo highlight recent advancements in the management of acute ischemic stroke patients with patent foramen ovale (PFO).Recent findingsOne significant recent development was publication of long-term follow-up data from the RESPECT trial demonstrating evidence in favor of PFO closure over medical management. This data subsequently led to FDA approval for AMPLATZER ™ septal occluder in the treatment of patients aged 18 to 60 years with both PFO and no other determined etiology for ischemic stroke, otherwise referred to as embolic stroke of undetermined source. Several subsequent closure trial results...
Source: Current Treatment Options in Cardiovascular Medicine - November 13, 2019 Category: Cardiology Source Type: research

Examining the evidence for PFO closure and novel oral anticoagulants for treatment of cryptogenic stroke.
Authors: Khan R Abstract Introduction: There has been considerable study assessing the treatment of cryptogenic stroke (CS) recently. This review examines the role of patent foramen ovale (PFO) closure in CS, while also discussing the evidence for alternative medical therapies in disease treatment.Areas Covered: PFO closure for treatment of CS has been assessed in 6 randomized controlled trials (RCTs). This review summarizes the background, results and limitations of these trials. Methodological and treatment-related differences in RCTs provide potential explanations for the discordance in outcomes observed between...
Source: Expert Review of Cardiovascular Therapy - February 23, 2020 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Deep Vein Thrombosis and Pulmonary Embolism Among Patients With a Cryptogenic Stroke Linked to Patent Foramen Ovale —A Review of the Literature
Conclusion: VTE can be detected in patients with CS linked to PFO. While –based on the presented literature–routine screening for VTE in patients with CS linked to PFO does not appear justified, history taking, and clinical exam should consider concomitant VTE. Whenever clinically suspected, the threshold to trigger ancillary testing for VTE should be low. Among patients with an acute PE and PFO, vigilance for new neurologic deficits should be increased, with a low threshold for brain imaging.
Source: Frontiers in Neurology - May 4, 2020 Category: Neurology Source Type: research

A Narrative and Critical Review of Randomized-Controlled Clinical Trials on Patent Foramen Ovale Closure for Reducing the Risk of Stroke Recurrence
Patent foramen ovale (PFO) is a common cardiac anatomic variant that has been increasingly found in young (<60 years) cryptogenic stroke patients. Despite initial neutral randomized-controlled clinical trials (RCTs), there have been four recent RCTs providing consistent data in favor of the efficacy and safety of PFO closure compared to medical therapy for secondary stroke prevention. However, taking into consideration the high prevalence of PFO, the low risk of stroke recurrence under medical treatment and the uncommon yet severe adverse events of the intervention, patient selection is crucial for attaining meaningful ...
Source: Frontiers in Neurology - June 3, 2020 Category: Neurology Source Type: research